Non-exclusive voluntary licensing to support affordability and supply

Gilead
Gilead’s early, systematic approach towards non-exclusive voluntary licensing helps efficient scale up and affordable supply of patented medicines in low- and middle-income countries.
Continue reading

Non-exclusive voluntary licensing outside of HIV/AIDS

Bristol-Myers Squibb, Gilead
Gilead and Bristol-Myers Squibb take the first moves, from companies in scope of the Access to Medicine Index 2016, outside non-exclusive voluntary licensing in HIV/AIDS.
Continue reading

Clarity in approach to IP management

AstraZeneca, GSK, Merck KGaA
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
Continue reading

Permitting supply of patented products beyond the agreed licensing territory

GSK
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.
Continue reading